Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to treatment.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
Clinical trials involving probiotics are failing to report on the safety and harms of these treatments.
Verge Genomics, the drug discovery startup we recently featured in our Top 5 Startups Disrupting Healthcare, has raised $32 million in Series A financing.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Even in light of the rising fears of “superbugs” in the world of big pharma, the marginal profits made through the development of antibiotics isn’t enough to justify the research.
Scientists have developed a technique that shows individual cancer cells in a tumour in real-time, revealing which cells that interact with a drug and which cells the drug fails to reach.
Scientists are taking advantage of the “self-homing” abilities of cancer cells and are creating armies of cancer-killing cells using CRISPR gene-editing.
Scientists have discovered a “big bang” of Alzheimer’s disease — the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects.